
The GLP-1 effect on MedTech
Strategy& has outlined strategic implications for the MedTech industry to thrive in the GLP-1 era.
Organizations should focus on a few differentiating core capabilities and build on them to gain a distinct competitive advantage and weather crises well. We support our clients on this path to success. Our service offering is based on three consulting approaches across industries.
Our consulting method empowers clients to transform their approach to creating, delivering, and capturing value - from ideation to implementation.
We identify and strengthen our clients' core capabilities and enable them to leverage their competitive advantage more efficiently.
We identify worthwhile investments and eliminate unnecessary costs, enabling our clients to strategically manage their cost structure and achieve sustained growth.
Our industry consultants combine strategic foresight, deep industry expertise, and practical strategic experience.
Our functional teams strengthen our clients’ core capabilities to seize competitive advantage.
Strategy& has outlined strategic implications for the MedTech industry to thrive in the GLP-1 era.
Strategy& conducts an annual consumer survey on payments and open banking with key insights into consumer behaviors across Europe.
Strategy& has analyzed how BioPharma companies must reinvent their business models to succeed in the emerging LIFEcare ecosystem.
Strategy& analyzed how launch and scale excellence drives pharma companies’ commercial success.